Apomorphine/Ziprasidone Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Apomorphine and ziprasidone can both affect your heart's rhythm.Apomorphine also increases the activity of dopamine in the brain. Ziprasidone may block the activity of dopamine in certain parts of the brain.
What might happen:
Taking apomorphine with ziprasidone may increase your risk of an irregular heartbeat, which may be life-threatening.Each medicine could also counteract the beneficial effects of the other, so one or both medicines may not work as well.
What you should do about this interaction:
Let your healthcare professional (e.g. doctor or pharmacist) know right away that you are using these medicines together. Let your doctor know right away if you notice any irregular heartbeat or have any dizziness or fainting episodes. Your doctor may want to perform an electrocardiogram (ECG) on you to check your heart rate and rhythm.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Apokyn (apomorphine hydrochloride) US prescribing information. Tercica, Inc. May, 2019.
- 2.Geodon (ziprasidone hydrochloride) US prescribing information. Pfizer Inc. May, 2021.
- 3.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 4.Marras C, Gruneir A, Wang X, Fischer H, Gill SS, Herrmann N, Anderson GM, Hyson C, Rochon PA. Antipsychotics and mortality in Parkinsonism. Am J Geriatr Psychiatry 2012 Feb;20(2):149-58.
- 5.Oertel WH Berardelli A Bloem Br etal. Chapter 15 - Late (complicated) Parkinson's disease in European Handbook of Neurological Management. 2011; Volume 1, 2nd Edition:237 - 267.
- 6.USDepartment of Health and Human Services Food and Drug Administration. ICH E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available at: https://www.fda.gov/media/71372/download October, 2005.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.